儿童急性髓系白血病造血干细胞移植的特征
本综述围绕儿童高危急性髓系白血病(AML)的异基因造血干细胞移植(HSCT)展开,讨论移植适应证、疾病与反应分层策略、移植前可测量残留病(MRD)低水平/阴性的重要性、预处理方案与移植物变量,以及利用移植物抗白血病(GvL)效应和靶向免疫治疗的新方法,并涉及移植毒性、移植物抗宿主病(GvHD)预防和治疗失败的管理。
要点
- 高危AML首次完全缓解(CR1)期,异基因HSCT被认为是首选的巩固策略。
- 移植前可测量残留病(MRD)低水平/阴性对移植结局具有关键重要性。
- 供受者配型、预处理方案、GvHD管理和支持治疗的进步改善了总体及移植结局。
核心结论
- 异基因造血干细胞移植显著改善了高危儿童急性髓系白血病患者的结局。
研究设计与样本
- 综述,综合讨论儿童急性髓系白血病的移植适应证与模式,涵盖过去、当前和未来的疾病及反应相关分层策略。
主要发现
- 在高危急性髓系白血病中,异基因造血干细胞移植是首次完全缓解(CR1)期首选的巩固策略,并为复发患者提供最佳治愈机会。
- 移植前可测量残留病(MRD)低水平/阴性具有关键重要性。
- 供受者配型、预处理方案、移植物抗宿主病(GvHD)管理和支持治疗的进步促进了总体结局和移植结局的改善。
关键数值与推荐
- 异基因造血干细胞移植的实施取决于不良细胞遗传学、分子异常、对一线治疗反应差,或复发或原发难治性疾病等因素。
临床怎么用
- 综述旨在为临床实践提供信息,并强调通过国际研究组的共同努力改善了结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly improved the outcome of children with high-risk (HR) acute myeloid leukemia (AML). Implementing allogeneic HSCT depends on numerous factors, including adverse cytogenetics, molecular abnormalities, poor response to first-line treatment, or relapsed or primary refractory disease. In HR AML, allogeneic HSCT is considered to be the consolidation strategy of choice in first complete remission (CR1) and offers the best chance of cure for patients with relapsed disease. Advances in donor/recipient typing, conditioning regimens, graft-versus-host-disease (GvHD) management, and supportive care have contributed to this improvement in overall-and transplant-outcome. This review will comprehensively discuss indications for HSCT and its modalities in pediatric AML by examining past, current, and future strategies for disease- and response-related stratification. We will examine the key importance of low/negative measurable residual disease (MRD) before transplantation and discuss conditioning regimens and graft variables, as well as novel approaches to harness the graft-versus-leukemia (GvL) effect, including targeted immunotherapy. The review will also address toxicities associated with HSCT, GvHD prophylaxis, and the management of treatment failure. Ultimately, this review seeks to inform clinical practice and highlights how improved outcomes have been achieved through the collective efforts of international study groups.
引用
- Rettinger E, Heckl D, Gibson B, et al. The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia. Leukemia. 2025. PMID: 40634512. doi:10.1038/s41375-025-02685-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。